Recognition of the antigen-presenting molecule MR1 by a Vδ3


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
07 12 2021
Historique:
accepted: 20 10 2021
entrez: 30 11 2021
pubmed: 1 12 2021
medline: 19 1 2022
Statut: ppublish

Résumé

Unlike conventional αβ T cells, γδ T cells typically recognize nonpeptide ligands independently of major histocompatibility complex (MHC) restriction. Accordingly, the γδ T cell receptor (TCR) can potentially recognize a wide array of ligands; however, few ligands have been described to date. While there is a growing appreciation of the molecular bases underpinning variable (V)δ1

Identifiants

pubmed: 34845016
pii: 2110288118
doi: 10.1073/pnas.2110288118
pmc: PMC8694053
pii:
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Ligands 0
MR1 protein, human 0
Minor Histocompatibility Antigens 0
Receptors, Antigen, T-Cell 0
Receptors, Antigen, T-Cell, alpha-beta 0
Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI148407
Pays : United States

Déclaration de conflit d'intérêts

Competing interest statement: J.R. is an inventor on patents describing MR1 tetramers and MR1 ligands.

Références

Science. 2005 Apr 8;308(5719):227-31
pubmed: 15821084
Immunity. 2016 Jan 19;44(1):32-45
pubmed: 26795251
J Synchrotron Radiat. 2002 Nov 1;9(Pt 6):401-6
pubmed: 12409628
J Exp Med. 1990 May 1;171(5):1597-612
pubmed: 2185330
Nat Immunol. 2020 Apr;21(4):400-411
pubmed: 32123373
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Commun. 2017 Mar 01;8:14760
pubmed: 28248310
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Cell Mol Immunol. 2013 Jan;10(1):50-7
pubmed: 23064104
Eur J Immunol. 1991 Apr;21(4):1053-9
pubmed: 1826884
Nat Immunol. 2016 May;17(5):531-7
pubmed: 27043408
Scand J Immunol. 1989 Jul;30(1):123-8
pubmed: 2526965
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
J Exp Med. 2000 Sep 4;192(5):741-54
pubmed: 10974039
Nature. 1998 Jan 29;391(6666):502-6
pubmed: 9461220
Methods. 2011 Sep;55(1):94-106
pubmed: 21821126
J Exp Med. 2008 May 12;205(5):1201-11
pubmed: 18443227
Clin Exp Immunol. 1994 Oct;98(1):78-82
pubmed: 7923889
PLoS One. 2013 Oct 04;8(10):e76008
pubmed: 24124528
Mediators Inflamm. 1999;8(6):305-12
pubmed: 10815619
Eur J Immunol. 1993 Apr;23(4):804-8
pubmed: 8384559
Nat Commun. 2019 May 21;10(1):2243
pubmed: 31113973
Blood. 2011 Jul 28;118(4):992-1001
pubmed: 21633088
J Immunol. 1994 Nov 1;153(9):3979-88
pubmed: 7930606
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
Nat Immunol. 2012 Sep;13(9):872-9
pubmed: 22885985
J Exp Med. 1991 Jun 1;173(6):1311-22
pubmed: 1827824
Science. 1998 Mar 13;279(5357):1737-40
pubmed: 9497295
Immunology. 2009 Feb;126(2):147-64
pubmed: 19125886
J Clin Invest. 1999 May 15;103(10):1437-49
pubmed: 10330426
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E556-65
pubmed: 25617367
J Exp Med. 2013 Oct 21;210(11):2305-20
pubmed: 24101382
Nat Immunol. 2013 Nov;14(11):1137-45
pubmed: 24076636
Nat Rev Immunol. 2015 Nov;15(11):683-91
pubmed: 26449179
Mediators Inflamm. 2001 Aug;10(4):179-89
pubmed: 11577994
J Immunol. 2013 Jul 1;191(1):30-4
pubmed: 23740951
Immunol Rev. 2007 Feb;215:59-76
pubmed: 17291279
Nat Commun. 2018 Nov 9;9(1):4706
pubmed: 30413689
Nat Immunol. 2017 Apr;18(4):402-411
pubmed: 28166217
Immunity. 2014 Apr 17;40(4):490-500
pubmed: 24703779
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3163-3168
pubmed: 28270598
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22944-22952
pubmed: 32868441
Blood. 2012 Apr 26;119(17):4013-6
pubmed: 22403253
Science. 2020 Feb 7;367(6478):
pubmed: 31919129
Science. 2019 Dec 20;366(6472):1522-1527
pubmed: 31857486
Nat Commun. 2013;4:2142
pubmed: 23846752
Nat Commun. 2018 May 2;9(1):1760
pubmed: 29720665
Biochem Soc Trans. 2021 Nov 1;49(5):1985-1995
pubmed: 34515758
J Exp Med. 2014 Jul 28;211(8):1585-600
pubmed: 25049336
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
Blood. 2011 Dec 22;118(26):6952-62
pubmed: 22045985
Immunity. 2013 Dec 12;39(6):1032-42
pubmed: 24239091
Immunity. 2012 Sep 21;37(3):524-34
pubmed: 22960222
Nat Immunol. 2020 Feb;21(2):178-185
pubmed: 31959982
Sci Immunol. 2018 Dec 14;3(30):
pubmed: 30552102
Nat Commun. 2014 May 15;5:3866
pubmed: 24832684
J Invest Dermatol. 1990 Jan;94(1):37-42
pubmed: 1688597
Trends Immunol. 2018 Jun;39(6):446-459
pubmed: 29680462
J Biol Chem. 2020 Oct 16;295(42):14445-14457
pubmed: 32817339
Int Immunol. 1999 Apr;11(4):545-52
pubmed: 10323207
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
J Immunol. 2015 Mar 1;194(5):2390-8
pubmed: 25637025
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
J Immunol. 2016 Feb 15;196(4):1933-42
pubmed: 26755823
Blood. 2012 Sep 13;120(11):2269-79
pubmed: 22767497
Nat Immunol. 2018 Apr;19(4):397-406
pubmed: 29531339
Eur J Immunol. 2012 Sep;42(9):2505-10
pubmed: 22829134
Nat Immunol. 2015 Mar;16(3):258-66
pubmed: 25642819

Auteurs

Michael T Rice (MT)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.

Anouk von Borstel (A)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.

Priyanka Chevour (P)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.

Wael Awad (W)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.

Lauren J Howson (LJ)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.

Dene R Littler (DR)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.

Nicholas A Gherardin (NA)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, University of Melbourne, Melbourne, VIC 3010, Australia.

Jérôme Le Nours (J)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.

Edward M Giles (EM)

Department of Paediatrics, Monash University, Clayton, VIC 3168, Australia.
Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medicine, Clayton, VIC 3168, Australia.

Richard Berry (R)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.

Dale I Godfrey (DI)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, University of Melbourne, Melbourne, VIC 3010, Australia.

Martin S Davey (MS)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; martin.davey@monash.edu jamie.rossjohn@monash.edu ben.gully@monash.edu.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.

Jamie Rossjohn (J)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; martin.davey@monash.edu jamie.rossjohn@monash.edu ben.gully@monash.edu.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.
Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.

Benjamin S Gully (BS)

Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; martin.davey@monash.edu jamie.rossjohn@monash.edu ben.gully@monash.edu.
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH